MAY 20, 2020 11:15 AM EDT | APAC MAY 21, 2020 2:15 PM CST

Spatial Landscape of the Immune Microenvironment in Metastatic Prostate Cancer using GeoMx™ Digital Spatial Profiler

Speaker

Abstract

Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the heterogeneity and lack of understanding of the immune composition and tumor microenvironment (TME) within and between molecular subtypes.

To characterize the immune TME of mPC, we obtained multiple metastases from patients with mPC belonging to multiple genomic subtypes and three phenotypes. Previous work defined the molecular subtype of each metastatic tumor by RNA-seq and whole exome sequencing, and patients were stratified to compare and contrast androgen receptor (AR) active tumors (AR+/NE-), neuroendocrine (NE) tumors (AR-/NE+), and double-negative tumors (AR-/NE-). An immuno-oncology RNA panel for the NanoString GeoMx™ Digital Spatial Profiler was used to determine the immune cell phenotypes within the tumor, in proximity to the tumor, and distant from the tumor margin.

Here we present a map of the metastatic landscape in mPC patients, focusing on the organization of the immune cells within the tissue. We use these maps to determine the immune cell compositions, spatial organization of metastatic niches, and spatial expression signatures that associate with the molecular subtypes of mPC. We further characterized the expression patterns between metastatic sites within the same patient, as well as the variation between patients.

Our study demonstrates a spatial genomics approach to defining the microenvironment landscape of molecular subtypes of mPC, potentially revealing patterns in the metastatic microenvironments that may predict the utility of immune-based therapies.

GeoMxTM DSP technology is for Research Use Only and not for use in diagnostic procedures.


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
NOV 30, 2021 11:00 AM PST
C.E. CREDITS
NOV 30, 2021 11:00 AM PST
Date: November 30, 2021 Time: 11:00am (PDT), 2:00pm (EDT) In the recent years, measurable residual disease (MRD) assessment on multiple myeloma patients has gained increasing relevance. After...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
Loading Comments...
Show Resources